Shots:

• The P-III study (DISCREET) evaluating the efficacy and safety of Otezla (30 mg, BID) vs. PBO in 289 patients with genital psoriasis and plaque psoriasis
• The result showed the improvement in the 1EPs of the modified sPGA-G response at@week16. 2EPs. with Otezla vs. PBO were also showed meaningful improvements in GPI-NRS response, affected BSA, Dermatology life quality index, and Static sPGA response @week 16 
• The patients completing the double-blind phase of the trial continued or switched to Otezla in the extension phase of the study and will be treated through week 32. The company is expecting to complete the study in the H1’22

/ article | Ref: Amgen | Image: Adweek